BORMANN-KENNEDY BARBARA-JEAN ANNE sold 11.2% of their position (16K shares) of XERIS BIOPHARMA HOLDINGS, INC. on the open market
Open‑market sale worth $97.5K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 6/5/2026ACC: 0001635065-26-000002
Director
Since Oct 2021
+41.19K
Net shares
Net buyer
$97.5K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
57.19K acquired · 16K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
−16K
Price / share
$6.09
Trade value
$97.51K
% of position
11.2%
6/4/2026
142.50K→126.50K
Common Stock
Direct
Shares
+24.19K
Price / share
—
Trade value
—
% of position
19.1%
6/4/2026
126.50K→150.69K
Total
Net shares
+8.19K
Net value
-$97.51K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/4/2026 | S · Sale | −16K | $6.09 | $97.51K | 11.2% | 142.50K | 126.50K |
| Common Stock Direct | 6/4/2026 | A · Award | +24.19K | — | — | 19.1% | 126.50K | 150.69K |
| Total | +8.19K | -$97.51K | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
33K shares
Shares
+33K
Strike price
6.15
Held after
33K
Exercisable
—
6/4/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock33K shares | 6/4/2026 | A · Award | +33K | 6.15 | — | 33K |